NL195022C - Antilichamen en actieve fragmenten daarvan die dienen voor het hiermee versterken van B-celuitbreiding. - Google Patents

Antilichamen en actieve fragmenten daarvan die dienen voor het hiermee versterken van B-celuitbreiding. Download PDF

Info

Publication number
NL195022C
NL195022C NL8701371A NL8701371A NL195022C NL 195022 C NL195022 C NL 195022C NL 8701371 A NL8701371 A NL 8701371A NL 8701371 A NL8701371 A NL 8701371A NL 195022 C NL195022 C NL 195022C
Authority
NL
Netherlands
Prior art keywords
cells
cell
bcgf
antibodies
mab
Prior art date
Application number
NL8701371A
Other languages
English (en)
Dutch (nl)
Other versions
NL8701371A (nl
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of NL8701371A publication Critical patent/NL8701371A/nl
Application granted granted Critical
Publication of NL195022C publication Critical patent/NL195022C/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL8701371A 1986-06-13 1987-06-12 Antilichamen en actieve fragmenten daarvan die dienen voor het hiermee versterken van B-celuitbreiding. NL195022C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13
US87388486 1986-06-13

Publications (2)

Publication Number Publication Date
NL8701371A NL8701371A (nl) 1988-01-04
NL195022C true NL195022C (nl) 2003-06-18

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
NL8701371A NL195022C (nl) 1986-06-13 1987-06-12 Antilichamen en actieve fragmenten daarvan die dienen voor het hiermee versterken van B-celuitbreiding.

Country Status (22)

Country Link
JP (1) JPH0762040B2 (sv)
KR (1) KR910004100B1 (sv)
AT (1) AT398437B (sv)
AU (1) AU617087B2 (sv)
BE (1) BE1000587A4 (sv)
CA (1) CA1338781C (sv)
CH (1) CH676600A5 (sv)
CY (1) CY1681A (sv)
DE (1) DE3719398C2 (sv)
DK (1) DK173940B1 (sv)
FR (1) FR2607136B1 (sv)
GB (1) GB2191494B (sv)
GR (1) GR870930B (sv)
HK (1) HK10293A (sv)
IE (1) IE60486B1 (sv)
IL (1) IL82841A (sv)
IT (1) IT1208649B (sv)
LU (1) LU86919A1 (sv)
NL (1) NL195022C (sv)
PT (1) PT85073B (sv)
SE (1) SE504675C2 (sv)
SG (1) SG118992G (sv)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (en) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monoclonal antibody specific for monocytes and blast cells
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Also Published As

Publication number Publication date
IL82841A0 (en) 1987-12-20
SE8702463D0 (sv) 1987-06-12
AU617087B2 (en) 1991-11-21
GB8713650D0 (en) 1987-07-15
NL8701371A (nl) 1988-01-04
SG118992G (en) 1993-01-29
GR870930B (en) 1987-12-16
IE871563L (en) 1987-12-13
IE60486B1 (en) 1994-07-27
IL82841A (en) 1992-11-15
GB2191494A (en) 1987-12-16
CH676600A5 (sv) 1991-02-15
DE3719398A1 (de) 1988-01-28
PT85073B (pt) 1990-07-31
GB2191494B (en) 1990-08-22
FR2607136A1 (fr) 1988-05-27
SE8702463L (sv) 1987-12-14
KR910004100B1 (ko) 1991-06-22
JPS6480299A (en) 1989-03-27
SE504675C2 (sv) 1997-04-07
DK173940B1 (da) 2002-03-04
ATA151387A (de) 1994-04-15
HK10293A (en) 1993-02-19
JPH0762040B2 (ja) 1995-07-05
DK302287A (da) 1987-12-14
CY1681A (en) 1993-10-10
DK302287D0 (da) 1987-06-12
AT398437B (de) 1994-12-27
PT85073A (en) 1987-07-01
AU7421487A (en) 1987-12-17
IT1208649B (it) 1989-07-10
IT8720899A0 (it) 1987-06-12
BE1000587A4 (fr) 1989-02-14
LU86919A1 (fr) 1989-03-08
KR880000582A (ko) 1988-03-28
FR2607136B1 (fr) 1989-09-15
DE3719398C2 (de) 1996-03-28
CA1338781C (en) 1996-12-10

Similar Documents

Publication Publication Date Title
Ledbetter et al. Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression.
US5182368A (en) Ligands and methods for augmenting B-cell proliferation
US5786456A (en) Bp 50-specific antibodies and fragments thereof
Clark et al. Activation of human B cells mediated through two distinct cell surface differentiation antigens, Bp35 and Bp50.
Perussia et al. Human natural killer cells analyzed by B73. 1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73. 1.
Fleischer A novel pathway of human T cell activation via a 103 kD T cell activation antigen.
US5601819A (en) Bispecific antibodies for selective immune regulation and for selective immune cell binding
Yokochi et al. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas.
Ledbetter et al. Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40).
Perussia et al. A human NK and K cell subset shares with cytotoxic T cells expression of the antigen recognized by antibody OKT8.
Freedman et al. B7, a B-cell-restricted antigen that identifies preactivated B cells.
Harada et al. Identification of early plasma cells in peripheral blood and their clinical significance
Clark et al. Activation of human B cell proliferation through surface Bp35 (CD20) polypeptides or immunoglobulin receptors.
Ledbetter et al. Surface phenotype and function of tonsillar germinal center and mantle zone B cell subsets
Degos et al. Syndrome of neutrophil agranulocytosis, hypogammaglobulinemia, and thymoma
Diaz Jr et al. Monocyte-dependent regulation of T lymphocyte activation through CD98.
JPH0638789A (ja) 抗ｃｄ３刺激ｔ細胞の増殖を阻害するハイブリドーマおよびモノクローナル抗体
Kirsch et al. The pattern of expression of CD147/neurothelin during human T‐cell ontogeny as defined by the monoclonal antibody 8D6
NL195022C (nl) Antilichamen en actieve fragmenten daarvan die dienen voor het hiermee versterken van B-celuitbreiding.
Yamamoto et al. Induction of Tac antigen and proliferation of myeloid leukemic cells by ATL-derived factor: comparison with other agents that promote differentiation of human myeloid or monocytic leukemic cells
de Palazzo et al. Potentiation of tumor lysis by a bispecific antibody that binds to CA19-9 antigen and the Fcγ receptor expressed by human large granular lymphocytes
Payne et al. Lymphocyte markers in non-Hodgkin's lymphomas
US5028424A (en) Antibodies to receptor and antigen for natural killer and non-specific cytotoxic cells
Jewett et al. Pentoxifylline suppresses interleukin-2-mediated activation of immature human natural killer cells by inhibiting endogenous tumor necrosis factor-alpha secretion
EP0325489B1 (en) Leu 23: Monoclonal antibody for monitoring leukocyte activation

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
NP1 Patent granted (not automatically)
V4 Discontinued because of reaching the maximum lifetime of a patent

Effective date: 20070612